{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:03:04Z","timestamp":1774119784751,"version":"3.50.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1053\/j.seminoncol.2013.12.011","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T09:15:59Z","timestamp":1386839759000},"page":"40-56","source":"Crossref","is-referenced-by-count":41,"title":["Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy"],"prefix":"10.1053","volume":"41","author":[{"given":"Sukhmani K.","family":"Padda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Trakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2013.12.011_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib3","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.07-1378","article-title":"American College of Chest P. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Scott","year":"2007","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PPO.0b013e31820b6d27","article-title":"Is surgical morbidity decreased with minimally invasive lobectomy?","volume":"17","author":"Park","year":"2011","journal-title":"Cancer J"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtcvs.2009.08.026","article-title":"Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database","volume":"139","author":"Paul","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtcvs.2009.04.026","article-title":"Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy","volume":"138","author":"Villamizar","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib7","doi-asserted-by":"crossref","first-page":"202S","DOI":"10.1378\/chest.07-1362","article-title":"American College of Chest P. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Detterbeck","year":"2007","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.prro.2010.07.001","article-title":"Stereotactic ablative radiotherapy: what\u2019s in a name?","volume":"1","author":"Loo","year":"2011","journal-title":"Pract Radiat Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2013.0084","article-title":"Non-small cell lung cancer, version 2.2013","volume":"11","author":"Ettinger","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/JTO.0b013e3181b9ecca","article-title":"Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials","volume":"4","author":"Lim","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2009.23.2272","article-title":"Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer","volume":"28","author":"Arriagada","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejcts.2004.03.041","article-title":"Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial","volume":"26","author":"Waller","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib15","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib16","first-page":"27","article-title":"Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine\/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) (asbtr 7501)","author":"Vincent","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib18","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib19","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib21","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1378\/chest.07-1359","article-title":"American College of Chest P. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition)","volume":"132","author":"Colice","year":"2007","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib22","series-title":"Difficult decisions in thoracic surgery","first-page":"67","article-title":"Optimal initial pathologic mediastinal staging of lung cancer: EUS, EBUS, mediastinoscopy","author":"Puri","year":"2011"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.athoracsur.2012.04.059","article-title":"Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections","volume":"94","author":"Boffa","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2009.05.039","article-title":"N2 disease in T1 non-small cell lung cancer","volume":"88","author":"Defranchi","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jtcvs.2007.07.060","article-title":"Data from the Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors","volume":"135","author":"Boffa","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.athoracsur.2005.06.066","article-title":"Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial","volume":"81","author":"Allen","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib27","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.athoracsur.2005.06.071","article-title":"Patterns of surgical care of lung cancer patients","volume":"80","author":"Little","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-U","article-title":"Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group","volume":"60","author":"Ginsberg","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib29","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1378\/chest.12-0790","article-title":"American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer","volume":"142","author":"Donington","year":"2012","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jtcvs.2004.04.030","article-title":"Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection","volume":"129","author":"Okada","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib31","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-007-9421-9","article-title":"Margin and local recurrence after sublobar resection of non-small cell lung cancer","volume":"14","author":"El-Sherif","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1510\/icvts.2008.178947","article-title":"Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients?","volume":"8","author":"Chamogeorgakis","year":"2009","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/SLA.0b013e318265819c","article-title":"Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis","volume":"256","author":"Ceppa","year":"2012","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.athoracsur.2010.02.026","article-title":"Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients","volume":"89","author":"Gopaldas","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1378\/chest.10-0859","article-title":"Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial","volume":"139","author":"Darling","year":"2011","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JTO.0b013e3182769aa8","article-title":"Validation of the IASLC\/ATS\/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients","volume":"8","author":"Yoshizawa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/modpathol.2010.232","article-title":"Impact of proposed IASLC\/ATS\/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases","volume":"24","author":"Yoshizawa","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ccm.2011.08.002","article-title":"Approach to the ground-glass nodule","volume":"32","author":"Detterbeck","year":"2011","journal-title":"Clin Chest Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jvir.2008.09.026","article-title":"Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy","volume":"20","author":"Kothary","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib41","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ijrobp.2004.07.665","article-title":"Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer","volume":"60","author":"Underberg","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib42","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.ijrobp.2004.07.718","article-title":"Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy","volume":"60","author":"Kimura","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2008.08.010","article-title":"Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy","volume":"91","author":"Guckenberger","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1754-9485.2010.02213.x","article-title":"High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer","volume":"54","author":"Watkins","year":"2010","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(03)00152-1","article-title":"The role of radiotherapy in treatment of stage I non-small cell lung cancer","volume":"41","author":"Qiao","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ijrobp.2005.03.073","article-title":"Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study","volume":"63","author":"McGarry","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study","volume":"75","author":"Fakiris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib49","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2008.21.5681","article-title":"Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy","volume":"27","author":"Baumann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib50","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.ijrobp.2005.05.034","article-title":"Clinical outcomes of a phase I\/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame","volume":"63","author":"Nagata","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib51","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/cncr.21747","article-title":"Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors","volume":"106","author":"Hara","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2006.04.013","article-title":"Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I\/II non-small-cell lung cancer","volume":"66","author":"Xia","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib53","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib55","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ijrobp.2012.07.2354","article-title":"Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly","volume":"84","author":"Shirvani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib56","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1200\/JCO.2010.30.0731","article-title":"Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis","volume":"28","author":"Palma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2009.04.080","article-title":"Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"77","author":"van der Voort van Zyp","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0b013e318252cfef","article-title":"Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer","volume":"7","author":"Lagerwaard","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijrobp.2010.08.056","article-title":"A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy","volume":"82","author":"Barriger","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib60","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ijrobp.2008.08.036","article-title":"Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who\u2019s at risk?","volume":"72","author":"Hoppe","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib61","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMc1203770","article-title":"Central-airway necrosis after stereotactic body-radiation therapy","volume":"366","author":"Corradetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib62","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijrobp.2011.10.071","article-title":"Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors","volume":"84","author":"Trakul","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib64","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijrobp.2011.06.2003","article-title":"Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small-cell lung cancer","volume":"83","author":"Lagerwaard","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib65","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ijrobp.2009.07.1751","article-title":"Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?","volume":"81","author":"Onishi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib66","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JCO.2009.25.0928","article-title":"Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer","volume":"28","author":"Grills","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-4-1","article-title":"Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study","volume":"4","author":"Hurkmans","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib68","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/JTO.0b013e318220cb8e","article-title":"A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer","volume":"6","author":"Ellis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib70","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-06-2446","article-title":"Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program","volume":"13","author":"Filipits","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib71","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2006.08.2867","article-title":"Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program","volume":"25","author":"Filipits","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib72","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1097\/01.JTO.0000283266.95918.6b","article-title":"IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC: D3-03","volume":"2","author":"Pirker","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib73","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1097\/01.JTO.0000283366.53929.20","article-title":"Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial: PD2-3-4","volume":"2","author":"Brambilla","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib74","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-09-2204","article-title":"MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer","volume":"16","author":"Kamal","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib75","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1078-0432.CCR-06-1503","article-title":"Class III beta-tubulin expression and benefit from adjuvant cisplatin\/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10","volume":"13","author":"Seve","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib76","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.12.6953","article-title":"Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer","volume":"25","author":"Tsao","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib77","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","article-title":"Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"31","author":"Shepherd","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib78","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2012.43.0900","article-title":"ERCC1 and RRM1: ready for prime time?","volume":"31","author":"Besse","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib79","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib80","doi-asserted-by":"crossref","first-page":"e25164","DOI":"10.1371\/journal.pone.0025164","article-title":"Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations","volume":"6","author":"Hubner","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib81","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1158\/1078-0432.CCR-11-0209","article-title":"EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor\u2014a novel antibody for immunohistochemistry or AQUA technology","volume":"17","author":"Mascaux","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib82","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/jnci\/dji427","article-title":"Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis","volume":"97","author":"McCabe","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib83","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib84","first-page":"31","article-title":"Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup (abstr 7505)","author":"Soria","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds385","article-title":"Customized adjuvant chemotherapy prognostic and predictive factors (abstract 77IN)","author":"Bepler","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib86","article-title":"O28.08 Biomarker (ERCC1 and RRM1)-based decision-making algorithm for adjuvant chemotherapy in stage I non-small-cell lung cancer (NSCLC) (SWOG-0720, NCT00792701)","author":"Zinner","year":"2011","journal-title":"Presented at: 14th World Conference on Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib87","article-title":"International tailored chemotherapy adjuvant trial: Itaca trial (abstract TPS7109)","volume":"30","author":"Novello","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2407-7-77","article-title":"Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol","volume":"7","author":"Kreuter","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2003.09.004","article-title":"Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC)","volume":"43","author":"Nakagawa","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib90","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ijc.11014","article-title":"New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction","volume":"104","author":"Shintani","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib91","first-page":"797","article-title":"Excavation of a buried treasure\u2014DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues","volume":"26","author":"Klopfleisch","year":"2011","journal-title":"Histol Histopathol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.46.9783","article-title":"Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine\/carboplatin in advanced non-small-cell lung cancer","author":"Bepler","year":"2013","journal-title":"J Clin Oncol. Epub"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib94","first-page":"6221","article-title":"BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis","volume":"63","author":"Quinn","year":"2003","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib95","article-title":"SCAT trial: phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer (abstract TPS208)","volume":"29","author":"Massuti","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib96","article-title":"Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (abstract 7011)","volume":"30","author":"Sanchez","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib97","article-title":"BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656\/GECP-BREC) (abstract LBA8002)","volume":"31","author":"Moran","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib98","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib99","author":"Wakelee","year":"2011","journal-title":"Presented at: 14th World Conference on Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib100","article-title":"Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC) (abstract 7013)","volume":"29","author":"Wakelee","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib101","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF01246677","article-title":"Structure, chromosomal localization, and expression of 12 genes of the MAGE family","volume":"40","author":"De Plaen","year":"1994","journal-title":"Immunogenetics"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib102","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3816\/CLC.2009.n.052","article-title":"MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy","volume":"10","author":"Tyagi","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib103","article-title":"MO21.08 Patient and tumor characteristics impacting on MAGE-A3 expression: screening data from the MAGRIT phase III trial","author":"Kim","year":"2011","journal-title":"Presented at: 14th World Conference of Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.43.7103","article-title":"Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results","author":"Vansteenkiste","year":"2013","journal-title":"J Clin Oncol. Epub"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib105","article-title":"The European Thoracic Oncology Platform Lungscape project: clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer (abstr 7514)","volume":"31","author":"Peters","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib106","article-title":"Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts) (abstract 8000)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib107","article-title":"A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC) (abstr 8019)","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7513","article-title":"Custom (molecular profiling and targeted therapy for advanced non-small cell lung cancer, small cell lung cancer, and thymic malignancies) trial (abstract 7513)","volume":"31","author":"Giaccone","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib109","unstructured":"Kerr KN, Dafni U, O\u2019Byrne K, Dooms C, Marchetti A, Sasano I, et al. ALK immunohistochemistry and fluorescence in-situ hybridization in Lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at: 15th World Conference of Lung Cancer. 2013 October 28 (Sydney, Australia)."},{"key":"10.1053\/j.seminoncol.2013.12.011_bib110","article-title":"Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients (abstract 8020)","volume":"31","author":"Ali","year":"2013","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib111","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib112","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib114","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JTO.0b013e318202bffe","article-title":"Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations","volume":"6","author":"Janjigian","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib116","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/JTO.0b013e31826bb7b2","article-title":"Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib","volume":"7","author":"D\u2019Angelo","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib117","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00001813-200511000-00012","article-title":"Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer","volume":"16","author":"Tsuboi","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib118","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 (LBA7005)","volume":"28","author":"Goss","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib119","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib120","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib121","article-title":"O28.01 select biomarker analyses of completely resected NSCLC tumors from enrolled patients in an adjuvant erlotinib (Tarceva) clinical trial (RADIANT)","author":"Richardson","year":"2011","journal-title":"Presented at: 14th World Conference on Lung Cancer"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib122","article-title":"The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) (abstract 7010)","volume":"30","author":"Neal","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib123","article-title":"Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L) (abstract TPS7110)","volume":"30","author":"Tada","year":"2012","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2013.12.011_bib124","unstructured":"Govindan R. Lung cancer: molecular profiling and genomics. Presented at: ASCO Annual Meeting; 2013 May 31; Chicago, IL."},{"key":"10.1053\/j.seminoncol.2013.12.011_bib125","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2009.26.4325","article-title":"Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer","volume":"28","author":"Zhu","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:18:32Z","timestamp":1597191512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0093775413002212"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.12.011","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}